Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO OTCMKTS:CYDY NASDAQ:NKTR NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.08+11.2%$1.94$0.40▼$2.66$251.63M0.411.15 million shs998,733 shsCYDYCytoDyn$0.33+6.5%$0.28$0.21▼$0.45$424.42M1.152.72 million shs955,924 shsNKTRNektar Therapeutics$81.89-1.8%$77.37$7.99▼$109.00$2.81B1.241.23 million shs722,323 shsPCRXPacira BioSciences$23.15-2.1%$23.36$18.80▼$27.64$930.18M0.32591,890 shs513,960 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%+10.00%-1.32%-8.78%+292.03%CYDYCytoDyn0.00%+0.10%+10.16%+24.50%-3.76%NKTRNektar Therapeutics0.00%-1.96%+11.04%+126.49%+817.16%PCRXPacira BioSciences0.00%-7.26%+1.68%+12.57%-6.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.08+11.2%$1.94$0.40▼$2.66$251.63M0.411.15 million shs998,733 shsCYDYCytoDyn$0.33+6.5%$0.28$0.21▼$0.45$424.42M1.152.72 million shs955,924 shsNKTRNektar Therapeutics$81.89-1.8%$77.37$7.99▼$109.00$2.81B1.241.23 million shs722,323 shsPCRXPacira BioSciences$23.15-2.1%$23.36$18.80▼$27.64$930.18M0.32591,890 shs513,960 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%+10.00%-1.32%-8.78%+292.03%CYDYCytoDyn0.00%+0.10%+10.16%+24.50%-3.76%NKTRNektar Therapeutics0.00%-1.96%+11.04%+126.49%+817.16%PCRXPacira BioSciences0.00%-7.26%+1.68%+12.57%-6.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60121.15% UpsideCYDYCytoDyn 0.00N/AN/AN/ANKTRNektar Therapeutics 2.73Moderate Buy$151.5085.00% UpsidePCRXPacira BioSciences 2.29Hold$29.4027.00% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, ALXO, NKTR, and CYDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026NKTRNektar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$151.00 ➝ $178.004/20/2026NKTRNektar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.004/7/2026PCRXPacira BioSciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/26/2026PCRXPacira BioSciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$27.00 ➝ $25.003/24/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$70.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/ACYDYCytoDynN/AN/A$0.00 per share93.04($0.08) per shareN/ANKTRNektar Therapeutics$55.23M50.03N/AN/A$4.41 per share18.57PCRXPacira BioSciences$726.41M1.25$3.78 per share6.13$16.62 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.90N/AN/AN/AN/A-182.01%-113.63%N/ACYDYCytoDyn$3.74M-$0.03N/AN/AN/AN/AN/A-182.93%N/ANKTRNektar Therapeutics-$164.08M-$10.20N/AN/AN/A-284.18%-308.94%-58.99%N/APCRXPacira BioSciences$7.03M$0.12192.939.85N/A0.70%10.24%5.47%N/ALatest PCRX, ALXO, NKTR, and CYDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million3/12/2026Q4 2025NKTRNektar Therapeutics-$2.69-$1.78+$0.91-$1.78$10.44 million$21.81 million3/9/2026Q4 2025ALXOALX OncologyN/A-$0.42N/A-$0.42N/AN/A2/27/2026Q4 2025ALXOALX Oncology-$0.38-$0.42-$0.04-$0.42N/AN/A2/26/2026Q4 2025PCRXPacira BioSciences$0.85$0.57-$0.28$0.04$201.93 million$196.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.172.072.07CYDYCytoDynN/A0.370.37NKTRNektar TherapeuticsN/A4.974.97PCRXPacira BioSciences0.564.733.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CYDYCytoDyn5.06%NKTRNektar Therapeutics75.88%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%CYDYCytoDyn1.00%NKTRNektar Therapeutics2.50%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.30 millionOptionableCYDYCytoDyn201.37 billion1.36 billionNot OptionableNKTRNektar Therapeutics22033.74 million32.90 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionablePCRX, ALXO, NKTR, and CYDY HeadlinesRecent News About These CompaniesPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from AnalystsMay 9 at 4:38 AM | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 8:00 AM | globenewswire.comPacira BioSciences Mails Letter to StockholdersMay 5, 2026 | globenewswire.comComparing Pacira BioSciences (NASDAQ:PCRX) & Hoth Therapeutics (NASDAQ:HOTH)May 5, 2026 | americanbankingnews.comAssessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World DataMay 3, 2026 | uk.finance.yahoo.comUniversal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRXMay 2, 2026 | marketbeat.comPharmaCorp Completes Acquisition of Pharmacy Files in Western CanadaMay 1, 2026 | globenewswire.comRoyal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceMay 1, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst UpgradeMay 1, 2026 | marketbeat.comNeedham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00May 1, 2026 | marketbeat.comPacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...May 1, 2026 | finance.yahoo.comPacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestonesMay 1, 2026 | seekingalpha.comPacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSApril 30, 2026 | marketbeat.comPacira BioSciences Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comPacira BioSciences, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPacira BioSciences Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comPharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline UpdateApril 30, 2026 | globenewswire.comPharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial ResultsApril 29, 2026 | globenewswire.comPacira BioSciences Files Definitive Proxy Materials and Mails Letter to ShareholdersApril 28, 2026 | globenewswire.comDo options traders know something about Pacira BioSciences stock we don't?April 27, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, ALXO, NKTR, and CYDY Company DescriptionsALX Oncology NASDAQ:ALXO$2.08 +0.21 (+11.23%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.98 -0.10 (-4.81%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.CytoDyn OTCMKTS:CYDY$0.33 +0.02 (+6.45%) As of 05/8/2026 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Nektar Therapeutics NASDAQ:NKTR$81.89 -1.48 (-1.78%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$82.10 +0.21 (+0.26%) As of 05/8/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Pacira BioSciences NASDAQ:PCRX$23.15 -0.49 (-2.07%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$23.18 +0.04 (+0.15%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
